The global OTC Cough, Cold & Allergy Medicine Market was valued at USD XX million in 2017 and is expected to reach a valuation of approximately USD XX million by 2025, riding on the back of a strong CAGR of XX% during the forecast period. Over the cough refer to medicine products that are used as a remedy for symptoms of flu, cold, and allergies that include nasal stuffiness and congestion, runny noses, sneezing, sore throat, and cough. The main reasons of these ailments are common cold, allergic rhinitis, influenza virus, fever and sinus infections.
The global OTC cough, cold & allergy medicine market consists of primary participants which include Sanofi-Aventis, Johnson & Johnson Service, Inc., Reckitt Benckiser Group Plc., Novartis AG, GlaxoSmithKline Plc., AstraZaneca Plc., Pfizer Inc., Sun Pharmaceutical Industries Ltd., Prestige Brands Holdings, Inc., Procter & Gamble Co., Bristol-Myers Squib Co., Merck & Co., and Allergen among others.
OTC Cough, Cold & Allergy Medicine Market Key Segments:
Market segmented based on Product Type:
On the basis of Dosage:
On the basis of Sales Channel:
On the Basis of Region:
Rest of Europe
Rest of Asia-Pacific
Rest of Latin America
Middle East and Africa (MEA)
Rest of MEA
The global OTC cough, cold & allergy medicine market growth is witnessing exponential gains due to factors such as increased governmental programs, better healthcare facilities and rising number of immunosuppressed persons which are expected to accelerate the growth of the market. Also, increasing global geriatric population, strict regulations enforcing consumer safety and mounting usage of cold & cough medications for minor physical issues is expected to bolster the growth of the market. The other factors leading to the market growth comprise of high penetration rate of the OTC drugs in emerging economies, favorable regulatory framework, and increasing shift of pharmaceutical companies to switch to OTC drugs from Rx drugs.